Com­pro­mised drug lot im­pacts Jasper's chron­ic hives study, stock falls

Jasper Ther­a­peu­tics’ stock crashed on Mon­day morn­ing af­ter the biotech said is­sues with a drug prod­uct lot im­pact­ed da­ta in a Phase 1b/2a clin­i­cal tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.